Aspirin Therapy In Neurological Disorder Such As Migraine And Alzhemeirs Disease
Main Article Content
Abstract
Aspirin, a widely used nonsteroidal anti-inflammatory medication, has a long history of therapeutic applications in pain relief, fever reduction, and inflammation management. Recent research has expanded its potential utility in treating neurological conditions such as migraines and Alzheimer's disease. For migraine management, aspirin's mechanism of action involves the suppressing the production of prostaglandins, a key factor in migraine-related inflammation and pain. Clinical trials have demonstrated its effectiveness in reducing the intensity and frequency of migraine attacks. Aspirin, especially when combined with metoclopramide, has proven to be a valuable treatment option for acute migraine episodes. In the case of Alzheimer's disease, which exhibits neurodegeneration, aspirin's anti-inflammatory and antioxidant properties have generated interest in its potential as a preventive and therapeutic agent. While epidemiological studies and biological processes have suggested aspirin's potential benefits, randomized studies have raised concerns about the risks of bleeding, outweighing the potential advantages. This review article examines the latest research on aspirin's role in managing and preventing migraines and Alzheimer's disease. It also discusses the clinical research regarding aspirin's effectiveness, safety profile, and possible side effects in these neurological conditions. Finally, the article explores the directions for future research involving aspirin in relation to migraines and Alzheimer's disease.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clinical Medicine & Research. 2007;5(1):19-34.
Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Current Treatment Options Neurology. 2008;10(1):20-29
Wang J, Tan L, Wang HF, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. Journal of Alzheimer's Disease. 2015;44(2):385-396
Rehman SU, Shah SA, Ali T, Chung JI, Kim MO. Anthocyanins Reversed D-Galactose-Induced Oxidative Stress and Neuroinflammation Mediated Cognitive Impairment in Adult Rats. Molecular Neurobiology 2017;54(1):255-271.
Ng TP, Feng L, Yap KB, et al. Long-term usage of non-steroidal anti-inflammatory drugs and risk of cognitive impairment in older women. Alzheimer's & Dementia. 2013;9(4):5312-5418
PubChem. Aspirin. Nih.gov. Accessed September 19, 2023.
Rainsford KD. Aspirin and its related analgesic and anti-inflammatory compounds. Inflammop harmacology. 2018;26(4):1109-1130.
Bhatt DL, Grosser T, Dong JF, et al. Aspirin’s mechanisms of action and clinical application Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(3):22-32.
Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med. 2016;129(12):319-325.
Christiansen M, Grove EL, Hvas AM. Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives, Seminars in Thrombosis and Hemostasis. 2021;47(7):800-814.
Rose FC. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995;15 Suppl 15:1-3.
Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study Lancet Neurology. 2013;12(5):454-461
Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. The Journal of Neuroscience. 2015;35(17):6619-6629.
Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels [published correction appears in Science. 2015 Oct 2;350(6256):aad5166] [published correction appears in Science. 2015 Nov 20;350(6263):921]. Science. 2013;339(6123):1092-1095.
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive conditione Journal of Headache and Pain. 2019;20(1):117. Published 2019 Dec 23.
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.journal of natural medicine 2002;8(2):136-142.
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. The Journal of Clinical Investigation. 2004;113(10):1447-1455.
Takano T, Nedergaard M. Deciphering migraine. J Clin Invest. 2009;119(1):16-19.
Pritlove-Carson S, Palmer RM, Morgan PR, Floyd PD. Immunohistochemical analysis of cells attached to teflon membranes following guided tissue regeneration. Journal of Periodontology. 1992;63(12):969-973.
Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. The Journal of Anesthesia. 2019;33(1):131-139
Riesco N, Cernuda-Morollón E, Pascual J. Neuropeptides as a Marker for Chronic Headache. Current Pain and Headache Reports. 2017;21(4):18
Anapindi KDB, Yang N, Romanova EV, et al. PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models. Molecular and Cellular Proteomics. 2019;18(12):2447-2458.
Su M, Yu S. Chronic migraine: A process of dysmodulation and sensitizationMolecular Pain. 2018;14:1744806918767697.
Hsu YC, Lin KC, Taiwan Headache Society TGSOTHS. Medical Treatment Guidelines for Acute Migraine Attacks. Acta Neurologica Taiwanica. 2017;26(2):78-96.
Cameron C, Kelly S, Hsieh SC, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55 Suppl 4:221-235.
Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015;55(6):778-793.
Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. American Journal of Medicine. 2020;133(4):412-416.
Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. The Journal of the American Medical Association . 2007;297(13):1443-1454.
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Treatment of MigraineThe New England Journal of Medicine . 2019;381(23):2230-2241.
Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232.
Giamberardino MA, Affaitati G, Costantini R, Guglielmetti M, Martelletti P. Acute headache management in emergency department. A narrative review International Journal of Internal and Emergency Medicine2020;15(1):109-117.
Mirbaha S, Delavar-Kasmaei H, Erfan E. Effectiveness of the concurrent intravenous injection of dexamethasone and metoclopramide for pain management in patients with primary headaches presenting to emergency department. Adv J Emerg Med. 2017;1(1):e6.
Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;(4): CD008041.
The international classification of headache disorders. 2nd ed.Cephalalgia. 2004;24(suppl1):S9-S160.
Ingledue VF, Mounsey A, StevermerJJ. Priority updates from the research. literature from the family Physicians inquiries network PURLs ®. Nih.gov Accessed July 25, 2023.
Vane 1971 . Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology. 1971; 231(25):232–5.
Volans 1974 . Volans GN. Absorption of effervescent aspirin during migraine. British Medical Journal. 1974; 4(5939):265–8. [PubMed: 4425854]
Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. The Journal of the American Medical Association . 1990;264(13):1711-1713.
Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer's disease. Alzheimers Dementia. 2019;15(1):168-171.
Zilberzwige-Tal S, Gazit E. Go with the Flow-Microfluidics Approaches for Amyloid Research. Asian Journal of Chemistry2018;13(22):3437-3447.
Khoury R, Grysman N, Gold J, Patel K, Grossberg GT. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Expert Opinion on Investigational Drugs2018;27(6):523-533.
Goedert M. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349(6248):1255555. doi:10.1126/science.1255555
Yasojima K, Schwab C, McGeer EG and McGeer PL: Distri- bution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830, 226-236 (1999)
AD2000 Collaborative Group, Bentham P, Gray R, et al. Aspirin in Alzheimer’s disease (AD2000): a randomised open-label trial. Lancet Neurol. 2008;7(1):41-49.
Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer’s disease (AD2000): a randomised open-label trial. Lancet Neurology 2008;7(1):41–9.